Company / Return on Equity (ROE)
Oncology Institute, Inc. Return on Equity (ROE) History
FY2021-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Equity (ROE)
-1801.7%
FY2025
5-year range
-1801.7% / 0.1%
FY2021-FY2025
Trend
-1136.8%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Oncology Institute, Inc. reports negative total equity of -1801.7% in FY2025. Negative equity can occur when accumulated losses exceed contributed capital, as reported in the balance sheet from the SEC filing.
Based on SEC 10-K filings.
-1801.7% in FY2025 with a 3-year CAGR of -1791.2%.
Declined from 0.1% to -1801.7% over the past 2 years.
Return on Equity (ROE) over time
Growth rates
- 3-Year Change
- -1791.2pp
- 5-Year Change
- -
- 10-Year Change
- -
Key checks
Key Insights
- In FY2025, return on equity (roe) decreased 1136.8% year-over-year.
- Peak return on equity (roe) was recorded in FY2023.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Equity (ROE)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -1801.7% | -1136.8% |
| FY2024 | -145.7% | -121491.7% |
| FY2023 | 0.1% | +101.1% |
| FY2022 | -10.5% | +79.4% |
| FY2021 | -51.0% | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026